Wells Fargo upgraded Apellis (APLS) to Overweight from Equal Weight with a price target of $32, up from $29. The firm cites stabilizing Syfovre sales and its confidence in Empaveli’s launch following a doctor survey for the upgrade. The shares could rally 15%-20% on Empaveli’s growth, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on APLS:
- Cautious Outlook on Apellis Pharmaceuticals Amid Market Challenges and Financial Constraints
- Buy Rating for Apellis Pharmaceuticals: Long-Term Growth Potential Amidst Current Challenges
- Trump threatens new tariffs on drugs, kitchen cabinets, trucks: Morning Buzz
- Morning Movers: Pharma, truck stocks react to Trump tariff announcements
- Apellis downgraded to Sell from Neutral at Goldman Sachs